Form 4: MapLight CFO Vishwas Setia Receives Equity Awards

MapLight Therapeutics' Chief Financial Officer, Vishwas Setia, was granted restricted stock units and employee stock options as part of his compensation.

Summary

• Vishwas Setia, Chief Financial Officer of MapLight Therapeutics, Inc. (MPLT), was granted 7,730 restricted stock units (RSUs) and 31,395 employee stock options on February 5, 2026.
• The RSUs represent a contingent right to receive one share of voting common stock for each unit, with a transaction price of $0.
• The stock options have an exercise price of $15.70 per share.
• Following these transactions, Setia beneficially owns 395,549 shares of voting common stock directly and 31,395 derivative securities (stock options) directly.
• The RSU award vests 1/4th on January 1, 2027, and 1/16th on each subsequent April 1, July 1, October 1, and January 1, subject to continued service.
• The stock options vest 1/4th of the total shares on February 5, 2027, and 1/48th of the total shares each month thereafter, subject to continued service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices aimed at aligning management incentives with long-term shareholder value, without indicating any immediate operational or financial changes.

Positives

• The equity awards align the Chief Financial Officer's interests with those of shareholders, incentivizing long-term performance.
• The grants represent a significant component of executive compensation, reflecting confidence in the officer's continued service and contribution.
• The vesting schedules encourage retention of key management personnel over several years.

Negatives

• The RSU and option grants, while standard, could lead to minor future dilution for existing shareholders upon vesting and exercise.
• There is no immediate cash benefit to the reporting person from these grants; value is realized upon vesting and potential stock price appreciation.

Risks

• The value of the stock options and RSUs is subject to the future performance of MapLight Therapeutics' stock price.
• Vesting of both the RSUs and stock options is contingent upon the reporting person's continued service through each vesting date, posing a risk of forfeiture if employment ceases.

Future Outlook

The equity awards are structured with multi-year vesting schedules, indicating a long-term incentive for the Chief Financial Officer to remain with the company and contribute to its future growth and stock performance. The vesting dates extend into 2027 and beyond, aligning executive compensation with future strategic objectives.

Industry Context

StockSavvy.ai notes that granting restricted stock units and stock options to key executives like the Chief Financial Officer is a standard practice in the biotechnology and pharmaceutical industries. This compensation structure is designed to attract, retain, and motivate top talent by aligning their financial interests with the long-term success and shareholder value creation of the company. It is particularly common for growth-oriented companies like MapLight Therapeutics to utilize equity-based incentives.

Comparison to Industry Standards

• The use of RSUs and stock options as a significant component of executive compensation is consistent with industry standards for publicly traded biotechnology companies.
• While specific grant sizes vary based on company stage, market capitalization, and individual executive roles, the structure of multi-year vesting for both RSUs and options is a common mechanism to ensure executive retention and long-term alignment, similar to practices observed at peers like Neurocrine Biosciences or Sage Therapeutics for their executive teams.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting and exercise of the equity awards, but also increased alignment of executive interests with long-term shareholder value.
• Employees: May signal stability in executive leadership and a commitment to equity-based compensation as a retention tool.
• Management: The Chief Financial Officer receives significant long-term incentives tied to the company's stock performance and continued service.

Next Steps

• The restricted stock units will begin vesting on January 1, 2027, with subsequent vesting dates quarterly thereafter.
• The employee stock options will begin vesting on February 5, 2027, with subsequent vesting monthly thereafter.
• The Chief Financial Officer will continue to serve in his role, subject to the terms of his employment and the vesting schedules.

Key Dates

Keywords

MapLight Therapeutics, MPLT, Vishwas Setia, Chief Financial Officer, Form 4, SEC filing, restricted stock units, RSU, stock options, equity compensation, insider transaction, vesting schedule